ReviewExpert opinion on therapeutic patents2019
A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications.
Review in Expert opinion on therapeutic patents, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Neutrophil elastase as a biomarker for bacterial infection in COPD.Respiratory research · 2019Trial
- Human Neutrophil Elastase and the Protein-Storm Axis: Reversible Synthetic Inhibitors in Inflammatory Disease.Molecules (Basel, Switzerland) · 2026Review
- Investigating the Ligand-Binding Properties of N-arylbenzimidazoles as Novel Elastase Inhibitors.ChemMedChem · 2026Article
- Therapies for bronchiectasis: mechanisms and potential effects.Frontiers in immunology · 2026Review
- Review
- Synergistic and Antagonistic Mechanisms ofMolecules (Basel, Switzerland) · 2025Article
- Neutrophil extracellular traps in homeostasis and disease.Signal transduction and targeted therapy · 2024Review
- Human Neutrophil Elastase: Characterization of Intra- vs. Extracellular Inhibition.International journal of molecular sciences · 2024Article
- Ebselen analogues with dual human neutrophil elastase (HNE) inhibitory and antiradical activity.RSC medicinal chemistry · 2024Article
- Investigating Polypharmacology through Targeting Known Human Neutrophil Elastase Inhibitors to Proteinase 3.Journal of chemical information and modeling · 2024Article
- Chondroitin Sulfate Proteoglycans Revisited: Its Mechanism of Generation and Action for Spinal Cord Injury.Aging and disease · 2024Review
- Natural Compounds as Protease Inhibitors in Therapeutic Focus on Cancer Therapy.Anti-cancer agents in medicinal chemistry · 2024Review
- Expression and purification of human neutrophil proteinase 3 from insect cells and characterization of ligand binding.PloS one · 2024Article
- High yield expression in Pichia pastoris of human neutrophil elastase fused to cytochrome B5.Protein expression and purification · 2023Article
- The Effects of 1-Molecules (Basel, Switzerland) · 2023Article
- Enzyme Inhibitors from Gorgonians and Soft Corals.Marine drugs · 2023Review
- Polysulfone Membranes Doped with Human Neutrophil Elastase Inhibitors: Assessment of Bioactivity and Biocompatibility.Membranes · 2023Article
- Novel Anti-Inflammatory Approaches to COPD.International journal of chronic obstructive pulmonary disease · 2023Review
- Eucalyptus-derived essential oils alleviate microbes and modulate inflammation by suppressing superoxide and elastase release.Frontiers in pharmacology · 2023Article
- Peptide Human Neutrophil Elastase Inhibitors from Natural Sources: An Overview.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionHuman neutrophil elastase (HNE) is involved in a variety of serious chronic diseases, especially cardiopulmonary pathologies. For this reason, the regulation of HNE activity represents a promising therapeutic approach, which is evident by the development of a number of new and selective HNE inhibitors, both in the academic and pharmaceutical environments. AREAS COVERED: The present review analyzes and summarizes the patent literature regarding human neutrophil elastase inhibitors for the treatment of cardiopulmonary diseases over 2014-2018. EXPERT OPINION: HNE is an interesting and defined target to treat various inflammatory diseases, including a number of cardiopulmonary pathologies. The research in this field is quite active, and a number of HNE inhibitors are currently in various stages of clinical development. In addition, new opportunities for HNE inhibitor development stem from recent studies demonstrating the involvement of HNE in many other inflammatory pathologies, including rheumatoid arthritis, inflammatory bowel disease, skin diseases, and cancer. Furthermore, the development of dual HNE/proteinase 3 inhibitors is being pursued as an innovative approach for the treatment of neutrophilic inflammatory diseases. Thus, these new developments will likely stimulate new and increased interest in this important therapeutic target and for the development of novel and selective HNE inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.